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Garuda 5 (khyung lnga): Ecologies of Potency and the
Poison-Medicine Spectrum of Sowa Rigpa’s Renowned
‘Black Aconite’ Formula
Jan M. A. van der Valk

This article focuses on ethnographic
work conducted at the Men-Tsee-Khang
(Dharamsala, India) on Garuda 5 (khyung lnga), a
commonly prescribed Tibetan medical formula.
This medicine’s efficacy as a painkiller and
activity against infection and inflammation
is largely due to a particularly powerful plant,
known as ‘virulent poison’ (btsan dug) as
well as ‘the great medicine’ (sman chen), and
identified as a subset of Aconitum species. Its
effects, however, are potentially dangerous or
even deadly. How can these poisonous plants
be used in medicine and, conversely, when
does a medicine become a poison? How can
ostensibly the same substance be both harmful
and helpful? The explanation requires a more
nuanced picture than mere dose dependency.
Attending to the broader ‘ecologies of
potency’ in which these substances are locally
enmeshed, in line with Sienna Craig’s Efficacy
and the Social Ecologies of Tibetan Medicine
(2012), provides fertile ground to better

understand the effects of Garuda 5 and how
potency is developed and directed in practice.
I aim to unpack the spectrum between sman
(medicine) and dug (poison) in Sowa Rigpa by
elucidating some of the multiple dimensions
which determine the activity of Garuda 5
as it is formulated and prescribed in India. I
thus embrace the full spectrum of potency—
the ‘good’ and the ‘bad,’ the ‘wanted’ and the
‘unwanted’—without presuming the universal
validity of biomedical notions of toxicity and
side effects.
Keywords: poison-medicine dichotomy, herbal toxicity, side
effects, aconite, Sowa Rigpa (Tibetan medicine).
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Introduction
There was once a kingdom in eastern India whose
inhabitants were bothered by lymph (chu ser) disorders and diseases caused by klu (subterranean or
aquatic elemental spirits) and by microorganisms;
it was possibly leprosy. Not knowing where to turn,
the king and his subjects took refuge in the Three
Jewels (Buddha, dharma, and sangha). As a result of
this observance, Garuda (a mythical bird) manifested to help the kingdom and cleared away the
obstacles faced by the people. When he was about
to die, Garuda offered his body as medicine so that
the people could continue to enjoy his blessings in
the form of pills to be taken internally or worn as
amulets. Garuda further promised that when the
materials of his body were exhausted, his blessings
would continue in the form of drugs. Thus it is said
that a ru ra (chebulic myrobalan) symbolizes Garuda’s flesh, ru rta (costus) symbolizes Garuda’s bones,
shu dag nag po (sweet flag) symbolizes Garuda’s
muscles, gla rtsi (musk) symbolizes Garuda’s blood,
and bong nga nag po (dark-blue aconite) symbolizes
Garuda’s heart. (Gyatso and Hakim 2010: 317)
Gyatso and Hakim (2010) present a convenient summary
of a myth narrating the origins of the medicine named
‘Garuda 5’ (khyung lnga), in which its five ingredients
correspond to the Garuda’s1 body parts. A dark-colored,
‘black aconite’ (bong nga nag po, or bongnak) is identified
as the heart of this mythical bird.2 The efficacy of this
commonly prescribed formula against acute afflictions
such as pain, infection and inflammation is in large part
due to this ‘heart.’ This particularly powerful plant that
is also named menchen (sman chen), ‘the great medicine,’
as well as tsenduk (btsan dug), ‘virulent poison,’ has been
equated with a subset of Aconitum species by contemporary
botanists and amchi (am chi, Sowa Rigpa practitioners;
van der Valk 2017: 52-54).3 Its strong potency, however, is
potentially dangerous or even deadly. How can poisonous
plants be used in medicine, or conversely: when does a
medicine become a poison? How can ostensibly the same
substance be both harmful and helpful? These questions
beg a more nuanced explanation than mere dose-dependency. Based on ethnographic observations and interviews
with amchi from the Men-Tsee-Khang (the Tibetan Medical
and Astrological Institute re-established in exile in 1961)4
in Dharamsala, India, I aim to show that the activity of
Garuda 5 and of potent substances in general is better
understood as enmeshed in local ecologies of potency
that do not presuppose a separation of ‘wanted’ and
‘unwanted’ effects.
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‘The dose makes the poison’5 is a famous adage formulated
by the sixteenth-century Renaissance scholar Paracelsus
(1493-1541), whose ideas lie at the foundation of modern
toxicology (Klaassen 2013: 5): (1) experimentation with
single chemical entities (a ‘toxicon,’ as opposed to
mixtures) is essential to determine their effects; (2) one
should distinguish between their therapeutic and toxic
properties, which (3) are not always clearly distinguishable, except by dose; and (4) the effects of chemicals have
a degree of specificity. In the standard toxicology science
textbook referenced above, a poison is introduced as:
[A]ny agent capable of producing a deleterious
response in a biological system, seriously injuring
function or producing death. This is not, however,
a useful working deﬁnition for the very simple
reason that virtually every known chemical has the
potential to produce injury or death if it is present
in a sufﬁcient amount. (Klaassen 2013: 17)
This points to the most fundamental concept in modern
toxicology, the dose-response relationship, although the
characteristics of exposure are known to further depend
on the route, site, duration, and frequency of exposure. From the toxicological perspective, all substances
are potentially poisons, including food and medicine.
Interestingly, the concept of ‘hormesis’ suggests that
“some nonnutritional toxic substances may also impart
beneﬁcial or stimulatory effects at low doses but that,
at higher doses, they produce adverse effects” (ibid: 25;
see Calabrese and Blain 2005). This results in a U-shaped
dose-response curve. In this sense, there is no clear-cut
poison/medicine dichotomy, but rather a spectrum of
biological effects (legislative, regulatory and medical
frameworks notwithstanding).
As a starting point for my critique on the applicability of
Paracelsian toxicology6 to Tibetan medical formulas, it is
important to note the ambivalence inherent in the scientific definition of poisons quoted above, as well as in the
complex nature of dose-response effects. Recent historical
investigations of the European medicine cabinet also
reveal “the multidimensional and dynamic role of drugs as
poison and vice versa” (Pieters 2018: 10), questioning dose
as the single determinant of their therapeutic/poisonous
effects. Indeed, it appears that “[T]he double-edged sword
of benefits and harms” (ibid: 12) has only been sharpened
by the maturation of the fields of toxicology, pharmacology and the burgeoning pharmaceutical industry, as
the quest for ‘pure ingredients,’ ‘precise dosages,’ and
narrowly defined effects has “actually opened new avenues
for mass poisoning in hospitals, nightlife, industry and the

battlefield.” These new chemical medications are founded
on a legacy of eighteenth- and nineteenth-century ‘heroic
medicine,’ with small doses that could be therapeutically effective but equally harmful. Pieters (2018) thus
emphasizes that not just the dose but also the context of
use defines what makes a poison, as he exemplifies in the
case of injection of a highly toxic and expensive chemotherapeutic fluid against deadly cancer with more-or-less
desperate patients and doctors in an increasingly commercialized medical/pharmaceutical industry.
The Gyüzhi (Rgyud bzhi, the Four Tantras)—Sowa Rigpa’s7
canonical medical text, probably redacted in its current
form in the fourteenth century (McGrath 2017)—however,
states that all substances on earth are potentially medicines: sa steng sman min ci yang yod ma yin (Men-Tsee-Khang
2011a: 185). It does not explicitly say that all substances
could be poisonous, yet it implicitly recognizes the beneficial potential of ostensibly toxic things. In the Gyüzhi,
medicine (sman) and poison (dug) are formally distinguished and separately discussed, for instance in the three
chapters of the Oral Instruction Tantra which detail the
classification of poisons and their cures. Anything beneficial can be referred to as men (sman) in Tibetan language,
while anything harmful is duk (dug). Yet, in Tibetan
medical theory and the subfield of medicine making (sman
sbyor) in particular, both terms acquire multiple and more
precise meanings (Sonam Dolma 2013). A comprehensive
account of the textual and theoretical bases underlying
men and duk is beyond the scope of this article. Instead, I
illustrate ethnographically how aspects of amchi discourse,
medicine-making and prescription problematize a rigid
poison/medicine dichotomy in practice, focusing on
issues of dosage and ‘side effects.’ The selected observations of reformulation, detoxification, compounding,
and clinical consultations that follow reveal the fluid,
contextual nature of potent substances. Dosage plays a
vital role, but it is not the central paradigm. Instead, these
practices locally shape the poison-medicine spectrum in
concert with multiple environmental and clinical factors.
Moreover, when amchi consider the dose of substances,
the focus is manifestly not on the ‘single chemical entities’
which are ‘active principles’ in modern toxicology and
biomedical pharmaceuticals (see Butler 2019; Tidwell and
Nettles 2019).
Leaving aside heavy metal contamination and poisoning—
of which the detection and media coverage played a role in
the politicization of Tibetan medicine in exile (Kloos 2008:
35-36, 2017: 148-150)—bongnak black aconite may well be
one of the potentially most toxic substances used in Sowa
Rigpa (Ma et al. 2015). Aconite poisoning, mainly in the

form of acute and possibly fatal cardio and neurotoxicity,
is a rare but well-known phenomenon, especially in East
Asian countries. It is often related to faulty identification
and processing of Chinese medicines (Chan 2009, 2011;
Nyirimigabo et al. 2015; Singhuber et al. 2009).8 These
studies, however, presume that the toxicity (and efficacy)
of aconite can be narrowed down to the binding to and
stimulation/inhibition of molecular receptors by aconitine
and related alkaloids. Yet none of the amchi I interviewed
and worked with think in these terms, which should not
come as a surprise. I argue that amchi attend to broader
understandings of potency and efficacy, which allows for
an attunement to ‘ecologies of potency’ in which pharmacists and their techniques, clinicians, patient bodies,
and local formulations of Garuda 5 and other substances
are enmeshed. In line with Sienna Craig’s Efficacy and the
Social Ecologies of Tibetan Medicine (2012), this perspective
provides fertile ground for better understanding the
effects of potent substances. Craig maps the multiple ways
in which human-environment interdependencies shape
the efficacy9 of Tibetan medicine in her multi-sited ethnography in Nepal and Tibetan areas in China.
She defines efficacy as:
[…] produced at the intersections of ritual action
and pharmacology, within distinct social ecologies.
Efficacy is a measurement of micropolitical power,
biopsychosocial effects, and cultural affect. It is
an intersubjective phenomenon, by which I mean
that one cannot really know whether a medicine or
therapeutic approach is efficacious until a practitioner makes and/or prescribes it, a patient uses it,
and then reacts to its use. (Craig 2012: 7)
I subscribe to her nuanced definition, which recognizes the
medico-ritual nexus and its social, sensorial, and material
embodiment. However, my focus here excludes ritual
contributions to efficacy (which in fact cannot be isolated
as such, also in the case of Garuda 5).10 It also does not
elaborate much on the complex of psychological, sociocultural and political-economic layers that infuses medicines
with power, which has constituted the main object of
study within the social sciences (see Coderey 2019).
Regrettably, “medical anthropology has seemed hitherto
to lack in full engagement with phytomedical reality,
and the acceptance that the health care practices of most
people on this planet depend on plants and animals” (Ellen
2006: 10), reflecting a problematic gap between medical
anthropology and ethnobotany (Waldstein and Adams
2006; Hsu 2010). Anthropologists of pharmaceuticals have
equally ignored materiality and “have left the discussion
of the drugs themselves and their physiological effects
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to biomedicine, accounted for socio-cultural aspects, and
thereby inadvertently reinforced the Cartesian dualism
that has set the agenda for the medical anthropological
project” (Hsu 2010: 23). I aim to bridge this problematic
divide through a heightened anthropological sensitivity
to plants and their properties, by highlighting some of the
more material, technical, and bodily dimensions which
determine the activity of the Garuda 5 formula.11 I also
expand Craig’s approach by including the full spectrum
of potency—the ‘good’ and the ‘bad,’ the ‘wanted’ and the
‘unwanted’—without presuming the universal validity of
biomedical notions of efficacy, toxicity, and side effects. In
this move, I am inspired by Margaret Lock’s ‘local biologies’ (Lock 1993, 2001: 483-487). Moving beyond the narrow
purview of ethnomedicine as well as meaning-centered
analyses, Lock saw the need early on to transcend the
nature/culture dichotomy and to question the epistemologically untouchable position of both the human body and
the medical sciences as ‘natural’ categories. Conceiving
the body ecologically as a dynamic microcosm based on
and overflowing in the local environmental macrocosm, I
argue that the Gyüzhi’s poison/medicine dichotomy is, in
effect, a spectrum of potent possibilities shaped by local
interactions and bodily configurations.
Academic coverage of what scholars have termed ‘Tibetan
pharmacology’—including its principles (Cardi 2005-2006,
Hofer 2014), its interrelationships with Buddhist ritual
(e.g., Gerke 2017), medical formularies and knowledge
transmission (Gerke 2018), and textual-historical analysis
of key concepts such as potency (nus pa) and substitution
(tshab) (Czaja 2015; 2017)—is significant and growing.
However, there is still a lack of close ethnographic attention to the material flows and frictions that make up the
potency of Tibetan medical substances (but see Blaikie
2014: 260-317, 2015; Blaikie et al. 2015; Chudakova 2015,
2017; Gerke 2013a). Building on Barbara Gerke’s longterm anthropological research on toxicity in Sowa Rigpa,
I recognize the crucial yet controversial entanglements
between the healing and harming potentials of substances.
A three-year project on pharmacological detoxification
methods with practitioners in India and Nepal led her to
investigate tsotel (btso thal), a highly processed and expensive organometallic complexed mercury sulfide compound
considered to be “the pinnacle of Tibetan pharmacology”
(Gerke 2013a: 123) and an essential ingredient for several
of the most complex, potent, and popular Tibetan medicines named ‘precious pills’ or ‘jewel pills’ (rin chen ril bu).
Gerke describes a dilemma faced by the Tibetan medical
community: tsotel (if processed correctly) is perceived
by them as the supreme medicinal substance, whereas
the mercury it contains is seen as the most dangerous
114 | HIMALAYA Spring 2019

neurotoxin in bioscientific circles and is implicated in
poisoning scandals. While Tibetans do not doubt its
benefits and are keenly aware of mercury’s toxicity in
unprocessed form, practitioners and institutions are challenged to prove its safety. This focal shift from efficacy to
safety was noticed by Gerke (2015) as a more general trend
in the biomedical and regulatory literatures on Asian
medicines (cf. Schrempf and Springer 2015, and
especially Kadetz 2015a, b).
Within medical anthropology, discourses of harm reduction, prevention, and risk have been found to reinforce
prejudice towards marginalized groups under the guise of
scientific objectivity, engendering complex dynamics and
politics of responsibility (Lock and Nichter 2002: 11-14).
In this article, I am sensitive to how modern biomedical
notions of risk can be mobilized to condemn ‘traditional
medicines’ through their conception as hazardous entities.
These sensitivities notwithstanding, biomedical notions of
‘risk’ and ‘side effect’ continue to play an insidious role in
what follows.
Ethnopharmacologist Nina Etkin (1992) critically analyzed
the reductionist biomedical definition of ‘side effects’ and
how these effects are interpreted and employed in unexpected ways in various sociocultural realities, as, in Etkin’s
seminal study on the indigenization of pharmaceuticals
by the Hausa of rural northern Nigeria. She argues that
“the primacy or subordination of effects depends on why
a medicine is administered, the intentions of the user
and prescriber, and the anticipated outcome—in short,
its cultural context” (Etkin 1992: 102). Contrary to the
general opinion, she finds, traditional medical systems
relying mainly on a pharmacopoeia of plants are markedly
sensitive to a multiplicity of effects. Indeed, as plantbased medicines are complex mixtures to which multiple
benefits are often ascribed, one would logically expect
there to be more ‘secondary’ effects as well. Herbalists
thrive on their awareness of this complex chemical
ecology (Johns 1996) far removed from the unrealistic
one-dimensional efficacy/toxicity or main/side effect of
highly concentrated pharmaceutical molecules. The myth
that pharmaceuticals have both stronger efficacy as well
as less side effects belies their sociocultural and biological
complexity. Secondary effects are relegated to a post-marketing rhetoric of ‘noncompliance’ and ‘misuse,’ masking
what are often purposeful appropriations by its users.
The following three sections are mainly based on my
doctoral fieldwork at the Men-Tsee-Khang, carried out
during several extended stays between 2013 and 2015
over a duration of roughly six months. My work there

was part of an officially sanctioned, mutually beneficial
collaboration. I taught Tibetan medical students botany
and staff English on a weekly basis for several months
and copy-edited a book on Tibetan medicinal plants (now
published: Tsultrim Kalsang 2016). In return, I was able to
access amchi working in the Materia Medica Department,
the Pharmaceutical Department (‘the pharmacy’), the
quality control lab, and the branch clinic of Gangchen
Kyishong (‘Gangkyi’). In the next heading, I first introduce how Men-Tsee-Khang amchi talk (or do not) about
scientifically defined risk and safety issues, relying on
textual ideals. I then move into the pharmacy, where it
turns out the potency of Garuda 5 in particular has to be
carefully adapted and crafted to local bodies and ecologies.
In the clinic, this medicine occupies an essential niche in
multi-compound prescriptions, which adds to the (social-)
ecological interactions that make its potency on a
different scale.
Textual Ideals and General Amchi Discourse on Safety
and Side Effects
On the third day of the Eighth ICTAM12 conference in
South Korea (September 9-13, 2013), Men-Tsee-Khang
Dr.13 Jamyang Dolma presented on ‘The Effectiveness and
Safety of Traditional Tibetan Medicine in the Treatment
of Challenging Diseases.’ Jamyang Dolma first emphasized
that Sowa Rigpa has a long history of empirical observation and research, which ensures its safety and efficacy,
and that practitioners do not question the reliability of the
classical texts nor the efficacy of their system. However,
globalization has brought the need for ‘evidence’ and
modern scientific studies even if these do not fit well with
traditional concepts. She then summarized the results of
clinical research undertaken by the Men-Tsee-Khang on
diabetes, hepatitis B and hypertension, and on processed
mercury. Her conclusion was that Tibetan medicine has
been proven to be very beneficial, that “it is totally safe,”
and that ‘authenticity’ is the key to its safety and efficacy.
About a week later, during a five-day introductory course
at Men-Tsee-Khang college (September 16-21, 2013), Dr.
Nyima Gyaltsen gave a lecture on the ‘Seven Limbs’ (yan
lag bdun), which detail the proper processing of herbs
into medicine according to the Four Tantras, and came
to a similar conclusion: “This [adhering to these textual
standards] is why everyone knows that Tibetan medicines
have no side effects.” These bold statements do not imply,
however, that amchi mindlessly accept that all their medicines are equally beneficial and by extension ‘safe’ in all
circumstances. Their aim here was to validate the efficacy
of properly produced Sowa Rigpa formulas vis-à-vis a
professional and student audience. In their statements,

Tibetan doctors assume that the practitioner-patient
interaction modulates prescription and usage. Dr. Rigzin
Sangmo from the Research & Development Department
exemplified this issue in her coming to terms with my
questions on the existence of side effects (interview, May
1, 2014): “for example, if you take cold [potency] medicines
for a very long time this might negatively affect your
digestion, but the practitioner can foresee this and adapt
the medicines accordingly.” The practitioner attunes
the qualities of the medicine to the constitution and
current situation of the patient, which I highlight further
as one of several opportunities to attune to the local ecologies of potency in the section on prescription practices
below. She disliked attributing side effects to Tibetan
medicines—one of the negative hallmarks of biomedical
drugs for which Sowa Rigpa is globally represented as a
natural, harmless complement or alternative—but did not
deny the possibility of ‘adverse reactions’ such as constitutional incompatibility or allergies.
Saying that Tibetan medicines have side effects is often
taken as a smear on the whole system, a lack of trust in the
practitioner’s traditional expertise, the classical texts or
even the Medicine Buddha in extremis. These statements
are part of a larger discursive trope expressed by both
practitioners and patients that influences healthcare
perceptions and decisions in the ubiquitous scenario
of medical pluralism in Dharamsala (Prost 2008: 36-41,
58-60). It also feeds into its globalization and spread into
alternative medicine and wellness markets (Janes 2002).
Stereotypically, biomedical pharmaceuticals are strong,
have rapid effects but might bring about adverse reactions
whereas Tibetan medicines are soft, slow-acting, natural,
and eradicate the root-cause of the disease (see Besch 2006:
191-194 for the same trope in Spiti).14 On top of that, what
a Tibetan in Dharamsala might consider a minor nuisance
as part of the healing process, European patients may
consider a problematic side effect. Engaging with Indian
road traffic made abundantly clear to me the very different
perceptions of risk and danger involved. As Dr. Tsultrim
Kalsang explained to me, taking medicines can have
unpleasant but necessary effects:
Sometimes people taking khyung lnga or other
strong medicine feel uncomfortable. It is not going
to worsen, sometimes it gives more [healing] effect
[in the end]. It takes time. If it continues like this,
then you have to stop [taking the medicine]. Two
or three days is ok. You need some movement,
without movement there is no effect. A little bit
worse, going down [purgation] or up [emesis]. If
I have a medicine for constipation and get loose
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motion, then the medicine gives effect. It doesn’t
mean there is another disease. It is the effect. If I
take medicine for constipation with no effect: no
movement, still the same as before, [then] what is
the use of medicine? (Interview, July 17, 2015)
During my fieldwork and in conversations with practitioners and patients, I came across only very few instances
where Tibetan medicines were deemed to have had a
negative influence on people’s health. However, some
reported unintended consequences of taking Garuda 5 are
relatively severe: burning and numbing sensations of lips
and tongue, itchy throat, dizziness, fainting, and weakened heart rhythm. Yet these effects have equally led to
adaptations in Garuda 5’s formulation, compounding and
prescription, as is detailed in the following two sections.
Reformulating, Detoxifying and Compounding Garuda 5
in the Pharmacy
When I asked Dr. Tsultrim Kalsang about the potential
dangers of taking Garuda 5 (interview, April 19, 2014), he
explained to me that the amount of Garuda 5 that will
be prescribed first of all depends on the condition of the
patient (being careful with children and the elderly) and
the nature and severity of the disease (a stronger disease
may need a higher dose). Depending on which subtype of
bongnak and its strength (as judged by root color, appearance, and sensation on the tongue), however, the method
for detoxification may vary. The quality and availability
of natural resources, itself determined by their habitat
and harvesting patterns, impacts pharmaceutical practice.
Practitioners need to be sensitive to this local ecology.
Tsultrim Kalsang, a Tibetan medicinal plant expert
stationed at the Materia Medica Department, has repeatedly been consulted by the pharmacy to confirm that the
roots are of the right kind. He informed me that prolonged
boiling of the roots in water, or treatment with cow milk
or urine can be undertaken, if necessary, to transform
poison into medicine.15
Dr. Penpa, who oversees the day-to-day production
of medicines at Men-Tsee-Khang’s Pharmaceutical
Department, added that effectively the quantity of
aconite is usually reduced to levels below what is
indicated in formularies:
It is the case. Because in earlier times people were
stronger, not because of [the presence of] this
poison. They could take this amount of tsenduk.
These days people more easily get the effect. So,
we have to reduce it. […] Not only for this tsenduk,
also for these burning cones: moxa. Before we used
big cones. Now we cannot use the bigger sizes, we
116 | HIMALAYA Spring 2019

use very small ones. Earlier, people were used to
hard work. They had good energy in their body,
they could take all this. These days people are more
relaxed. […] Usually tsenduk is not in huge quantity
in the medicine, but we had to reduce this [further]
slightly. (Interview, April 21, 2014)
“The bodies of people nowadays have become frail due
to a lack of manual labor,” was an observation echoed by
several Tibetan doctors I met. Undoubtedly taking the
harsh lifestyle of nomads and farmers on the high Tibetan
plateau as a reference for optimal health, medicines must
now be adapted to the ‘docile bodies’ (Langford 2007) of
Tibetan exile, Indian, and ‘Western’ patients. Following
Blaikie’s (2015) argument on the multiplicity and contingency of ‘classical formulas’ in real-world pharmacy
practice and the spate of research on industrial reformulation (Pordié and Gaudillière 2014; Pordié and Hardon
2015; Schrempf 2015), variations in the composition of
Garuda 5 should not come as a surprise. However, in
comparing the small number of English-language publications detailing Tibetan formulations, it seems that the
variation is relatively minor. Bhagwan Dash (1994), an
Ayurvedic scholar-physician, Smanla Phuntsog (2006), a
lineage-based Ladakhi amchi, and Jigme Tsarong (1986),
Tibetan exile and former Men-Tsee-Khang director,
basically agree on the formula. This may be due to the
standardizing effect of the Four Tantras,16 as well as widespread reliance on the Excellent Vase of Elixirs (Bdud rtsi’i
bum bzang) by Lhasa Mentsikhang’s founding director
Khyenrap Norbu (Mkhyen rab nor bu, 1883-1962). The
latter is a foremost reference for pharmacists operating in
Tibet, India, and beyond, especially on ingredient quantities which are seldom published (Khyenrap Norbu 2007:
150-151). Yet, when one compares these textual formulas
with an actualized composition of Garuda 5, a different
story emerges (Table 1). Nowadays at Men-Tsee-Khang’s
pharmacy, the amount of aconite is generally much lower
(from 25% to less than 10% of the total weight in this case),
and musk (gla rtsi) is substituted by the resin of gul nag
(the black type of gu gul, a primary component of Indian
dhoop incense).17 The aconite/myrobalan weight ratio is
1/5 instead of 1/2 in Khyenrap Norbu’s formulary, which
likely further decreases aconite’s toxicity (and potency) in
addition to the difference in amount in itself.18
On February 27, 2014, 634 kilograms of Garuda 5 was
compounded under Dr. Penpa’s supervision, following the
recipe outlined in Table 1. Arriving at the third ingredient,
menchen, he noted that: “This time we put not so much,
because it is very strong energy. […] These days first we
have to clean it, then we have to boil it for a little bit to
reduce this…how to say…potency, yes maybe duk.” This

Table 1. Comparison of an authoritative textual formula of Garuda 5 with an actualized composition at the Men-Tsee-Khang.19

Khyenrap Norbu’s ‘authentic Garuda 5’
(khyung lnga tshad ldan) textual formula

Men-Tsee-Khang’s actualized formula (batch compounded
on February 27, 2014, under supervision of Dr. Penpa)

a ru (Garuda’s flesh)

40 srang (50%)

a ru (Terminalia chebula Retz.), pitted fruit

250 kg (39%)

ru rta (bones)

10 srang (13%)

ru rta (Saussurea costus (Falc.) Lipsch.), root

unspecified

shu dag (tendons, rgyus pa)

6 srang (8%)

shu dag (Acorus calamus L.), root

unspecified

btsan dug (heart)

20 srang (25%)

sman chen (Aconitum sp.), tuberous root

55 kg (9%)

gla rtsi (blood)

3 srang (4%)

gul nag (Commiphora mukul (Hook. ex
Stocks) Engl.), resin

unspecified

79 srang (100%)

quote directly points to the potentially close relationship between potency (nus pa) and toxicity (duk), while
highlighting the need for manipulation of pharmacological
activity. Senior pharmacy doctors advise on how long the
roots should be boiled, depending on the nature of each
batch and their experience.20 Pharmacists must recognize
the impact of local ecologies (e.g., different subtypes and
potencies of Aconitum), but also pay attention to how these
interact with and shape lived bodies. Focusing on the use
of aconite in Garuda 5, we can therefore speak of local
ecologies of potency. Figure 1 offers a general overview of
the pill-making process at Men-Tsee-Khang’s pharmacy,
which I interpret as a step-wise modulation and optimization of potency (see van der Valk 2017: 236-238 for a more
detailed description).
As Dr. Nyima Gyaltsen indicated in an earlier quote, the
“seven essential limbs of standardization” (translation of
yan lag bdun in Men-Tsee-Khang 2011b: 135) play a central
role in the putative absence of ‘side effects’ in Sowa Rigpa
in general. The seven limbs are listed in the last of the Four
Tantras, in chapter 12 on herbal compounds, and include
dukdön (dug ’don), the ‘removal of toxic substances’ (ibid:
135). These unwanted portions of medicinal ingredients
(e.g., leaf petioles, flower sepals, fruit stones) are not
considered to be acutely poisonous in the pathological
sense, but their coarseness hampers the digestive fire (me
drod) and harms the body constituents (lus zungs bdun).
However, this relatively ‘simple pre-processing’ (following
Saxer 2013: 68) does not seem sufficient for tsenduk,

634 kg (100%)

which requires careful, extra attention. Although still
far removed from the complexity, duration, and cost of
processing or ‘taming’ (’dul ba) mercury (cf. Sonam Dolma
2013: 114-116; Gerke 2013a),21 Dr. Penpa stated that tsenduk
needs ‘real’ detoxification. As was confirmed by Dr. Tsering
Norbu, who worked in the pharmaceutical department for
several years in the early nineties, menchen roots are boiled
in distilled water at Men-Tsee-Khang but are sometimes
also used directly. He is the author of a large book of more
than six hundred pages in Tibetan that compiles materia
medica and the formulas in which they are represented
from classical Sowa Rigpa texts (Tsering Norbu 2005). He
found that boiling in water was not described as a detoxification method for menchen.22
Maybe some experienced doctors [in the past] did
it like that. But [another form of] detoxification is
mentioned. First you have to make ash, [still hot
with] fire in the wood. A little bit of fire. After all
the wood is burned, [take] a little bit of warm ash.
Put powder of Aconitum in a pan, then put it in the
ash, and cover [the pan] with paper. After a few
minutes, the paper becomes wet. The powder color
becomes a little yellow, then ... Not detoxified, not
like mercury. Mercury has many processes. [But its]
energy has become less, that is the idea.
(Interview, July 21, 2015)
Interestingly, Dr. Tsering Norbu specifies that, in the case
of aconite, the aim is to decrease its ‘energy’ (nus pa). The
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Figure 1. The main steps of rilbu (ril bu, rolled pill) production at Men-Tsee-Khang’s pharmacy, left to right and top to bottom. Pre-processing (in this
case, manual sorting of spang spos), weighing and dosing of raw materials (here of Tikta 8), grinding, mixing, pill rolling, size checking, drying (of Agar
35), and counting, labeling and packaging (Garuda 5).
(van der Valk, 2014)
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heat-based potency-modulating method he describes is
laid out in the text Lag len gces bsdus by Deumar Tendzin
Püntsok (De’u dmar Bstan ’dzin phun tshogs, born 1672,
Deumar Tendzin Püntsok 1970: 532-549). Tsering Norbu
said he has seen this being done at Lhasa Mentsikhang
when he was there in the eighties. Different processing
methods are currently used in different contexts, but
Tibetan doctors in Dharamsala are confident that there,
too, the potency of bongnak has been attenuated.23
Pre-processing, detoxification and compounding techniques are either described superficially or not at all,
even in major pharmacy or menjor (sman sbyor) textbooks
(Blaikie 2014: 267-270; Cardi 2005-2006: 99, 105). These
experientially-based ‘pith instructions’ (man ngag) are
orally transmitted and often considered secret, thus
inviting high diversity in practice.
Eventually, I discussed the issue with Dr. Penpa Tsering
(Interview, July 18, 2015). He is a very experienced and
well-known menjor expert who resigned from Men-TseeKhang to lead his own production named Kundey Khangsar
Tibetan Herbal Products, not far from Dharamsala.
Although he agrees with the other, more junior Dr. Penpa
currently working in the pharmacy that people were
stronger in ancient times, he claims it is not possible to
identify the variety of different bongnak subtypes on the
market reliably as Tsultrim Kalsang does. In line with
Tsering Norbu, Penpa Tsering maintains that menchen does
not need to be detoxified as is done in Ayurveda: arura,
Garuda 5’s principal ingredient, controls its toxicity. There
is considerable variation in potency due to harvesting
time and location, amongst other factors, and this should
be assessed by tasting and testing the effect of the Garuda
formula after compounding.
VDV: You say you have to know how toxic menchen
is to know the dose. How do you know how toxic it
is? Can you taste it or see it?
PT: No, no. [Only] after making the pills. We have to
see by experience how much we have to put. After
making the pills, we are trying them. If it is okay
[then we can use them], if the toxicity is high then
we don’t have to use that one. We can do like this
also: we mix [the pills] again, compounding, putting
less or not putting [extra] menchen. Putting other
things will lessen the toxicity.
Making and taking Garuda 5 is clearly not without danger
to pharmacists and patients. If adverse effects occur and
are reported, one is advised to have some Tibetan noodle
soup (thug pa) or yoghurt, and to rest. The dosage may also
be reduced, for instance from three or four to only one or
two small black pills. In the practical setting of menjor, safe

and potent medicines are not a given, but are the contingent result of a series of carefully executed procedures.
Experience, skill, and sensory perception are sine qua non
for the modulation of the poison-medicine spectrum. As
ethnopharmacological studies have shown, organoleptic
assessment is a key criterion for the classification, selection and medicinal use of plants that is both individually
and culturally specific, reflecting differing notions of
illness and efficacy (Pieroni and Torry 2007; Shepard 2004).
Nonetheless, as put forward by Etkin (1992: 103), indigenous healers in many places—and biomedical physicians to
some extent—are known to apply ‘side effects’ as
dosage markers, which is also the case for Garuda 5.25
As Cardi (2005-2006) details, Tibetan practitioners regard
single-ingredient herbal medicines as inferior in efficacy
and potentially more harmful compared to multi-compound formulas where the therapeutic actions of the
ingredients are coordinated, negative effects balanced out,
and where the composition may be adjusted to individual
patients. Throughout, the aim is to obtain a potent
medicine that is also ‘smooth’ (’jam). From a Tibetan
medical viewpoint, then, unwanted effects are likely to
arise if the medicines have been poorly manufactured
and/or unsuitably prescribed.
Prescribing Garuda 5 in the Clinic
An energetic seventy-year-old Indian woman from the
nearby village of Sidhbari entered the consultation room
while her husband waited outside. Dressed youthfully and
wearing strong perfume, she sat down and put her iPhone
on the office table. She immediately started summing up
her ailments in English interspersed with Hindi, describing
her serious skin disorder that had spread over her arms
and legs at the top of the list:
It is not psoriasis or scabies. An allopathic doctor
said it was allergic eczema, but I didn’t want the
cortisone. The skin peels off, but it keeps coming
back. I take thyroxin every day. I took Tibetan medicine for years for bronchial asthma, it got better
but was not completely cured.
(Observed consultation, May 6, 2014)
While taking the pulse, Dr. Sonam Wangmo noted that
internal fever was present; it was a very hot pulse. The
lady also had a mkhris pa (‘bile’) constitution. Sonam
Wangmo advised to avoid lemon and sour yoghurt. The
patient replied she was a strict lacto-vegetarian. Her
sleep was bad, and she wakes up every half hour. The
amchi summoned another senior female practitioner
from the adjacent room to discuss the case. Together they
concluded that there was indeed a chronic ‘hidden fever’
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(gab tshad) and that chuser (‘yellow fluid’) was disturbed.
The doctor explained to the patient that because of her
age, less strong medicines were advisable. The medicines
should be taken with hot water rather soon after eating.
After the patient had left, Dr. Wangmo explained to me
that taking high doses of strong medicine could result
in low blood pressure, which may lead to fainting. These
reactions are not considered side effects, but are instead
interpreted as a consequence of prescribing medicines
inappropriate for the patient’s current state. Thangchen 25
was prescribed in the morning time to purify the blood and
separate the hidden fever from it. After lunch, Ngülchu 18
was prescribed to reduce chuser and to ward off afflictions
by nāga (klu). Skin problems are commonly related to these
nāga serpent spirits (although this was not mentioned
to the patient), and here the processed mercury sulfide
complex is particularly effective. Two combinations to be
taken on alternate days were prescribed for the evening:
Gurgum 13 plus Khyung Nga Nila26 (for the liver and
impure blood and to fight lymph-related infection, respectively) and Pökar 10 (against itching skin) plus Khyung Nga
Nila. To smoothen the skin, Tripa lotion was prescribed.
I asked a number of amchi what Garuda 5 is commonly used
for, and the keywords I got back were ‘infection,’ ‘inflammation,’ and ‘pain’.27 Typical examples I was given were to
keep one pill in your mouth in case of painful toothache, or
to take a few against knee pain or acute headache caused
by srin (a technical term frequently applied to parasites
and pathogenic micro-organisms). Several amchi, as well
as patients, referred to Garuda 5 as “a sort of antibiotic”
with the formula’s fast-acting antibacterial effects in mind.
During my time observing consultations with Dr. Sonam
Wangmo at Gangkyi clinic (April-May 2014), I witnessed
more than a dozen cases where Garuda 5 was prescribed.
Amchi-la confirmed that Tibetan patients will specifically
ask for it when needed. Tibetan medicines, however, are
not usually prescribed as a single formula—already a
complex compound of processed natural ingredients—but
as a combination of formulas to be taken before breakfast,
after lunch and after dinner. On top of that, Garuda 5 is
one of few formulas that is compounded and prescribed
together with others, to be taken at the same time of day
(as in the consultation summarized above): a third-order
combination or compounding of compounds. Other examples of these ‘supercompounds’ include Pökhyung (Pökar
10 + Garuda 5), Pangkhyung (Pangyen 15 + Garuda 5),
Samkhyung (Samnor + Garuda 5), and Nyikhyung (Sendru
Nyikyil + Garuda 5), all of which are widely known and
used (cf. Penpa Tsering and Choelothar 2013). According
to Sonam Wangmo, who has more than fifteen years of
clinical experience, this complex ecology of substances
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is required to treat contemporary problems and diseases
that have become more complicated.28 In contrast to
nowadays, Dr. Wangmo added, senior doctors in ancient
times were very sure about their diagnosis and preferred
to wait and see the effect of single formulas, which they
may have prescribed three times a day for seven days.
Once again, the frailty of human bodies (and knowledge)
is mobilized to explain for changes in Tibetan medical
practice that seem to deviate from the classical ‘golden
age’ of the past. Such statements are influenced by a larger
Tibetan Buddhist and Hindu trope of degenerative times
(Skt. kaliyuga), which has shaped Sowa Rigpa’s entangled
intellectual history and innovation for centuries (Gyatso
2015: 7-8, 137-138). In line with Gyatso, prescribing Garuda
5 necessitates an empirical, medical mentality that gives
ample attention to “the local specificities of the natural
world” (ibid: 8); that is, to its local ecology of potency.
Conclusion
On camphor we have a very impressive saying in
Tibet: it is the king of the medicine, especially [due
to its] very cold and rough nature. But if you don’t
prepare it or compound it in a good way, it is very,
very harmful. It should not be like poison, but very
harmful. Because its rough nature increases rlung
(wind). Now, at present in Tibet, we really don’t
use that much camphor.29 […] The saying goes that
this king [of medicine] will be harmful more than
healing, kill more people than help people. […]
Tsenduk, [black] aconite, is the king of poison. This
will be helpful more than harmful. These two are
compared. (Dr. Tenzin Thaye, Deputy Head of MenTsee-Khang’s Pharmaceutical Department, Interview, April 30, 2014)
The above quote, related to me by Dr. Tenzin Thaye,
compares the effects of camphor and aconite—the respective kings of medicine and poison.30 It warns us that what
is beneficial and what is harmful is not straightforward
in Sowa Rigpa, and may even turn out to be opposite to
our expectations. So, was Paracelsus wrong? In the case of
Tibetan medical compounding and prescription practices,
what counts is the potency of mixtures and not the effect
of a single entity (see Schwabl and van der Valk 2019). It
is the processing of and interactions between ingredients,
and attunement to lived patient bodies, which ensures a
‘smooth’ medicine. A priori distinctions between therapeutic and toxic effects are mere conjecture. In
this dynamic ecology of potency, the dose remains
important but is not the ultimate criterion. These interwoven biological and cultural dimensions of efficacy and

toxicity have long been recognized and encapsulated in
non-dichotomous, ambiguous potency concepts such as
the Greek pharmakon (Rinella 2010), the Amazonian rao
(Shepard 2004) and the Zulu term muthi (Ashforth 2005).
Although Ayurveda and Chinese medicine have separate
words for ‘medicine’ and ‘poison’ like Sowa Rigpa, it is
now clear that this need not imply that their intentions
and outcomes can and should be easily distinguishable.31
To come to this conclusion, I built on Craig’s (2012) Social
Ecologies to unpack medicine/poison and ‘main’/’side’
effects as the contingent result of dynamic plant-practitioner-patient body interactions and practical modulations
of potency in the pharmacy and the clinic. These local
ecologies of potency are sensorial, at once social and
chemical, and involve multiple human and nonhuman
actors and labor.
Although biomedical definitions are spreading and hybridizing with Asian medicines, safety, efficacy and toxicity
remain situational, multi-dimensional concepts. The more
pressing question then becomes how negative effects
might be documented and averted by menjor experts and
in the clinic, where proper diagnosis of the patient plays a
central role in determining which medicines have suitable
activity profiles. The formulation of rilbu is a step-wise
potency modulation process that removes, transforms
and balances out or ‘smoothes’ the useless, coarse and
poisonous elements of materia medica. In the daily workings
of the pharmacy, however, practical and experience-based
decisions have to be taken on the exact details of this
process. Which types of aconite can be used as ‘the great
medicine’ (menchen), what amount, and should the roots
be pre-boiled or not? Different opinions and methods
abound, but all amchi agree that extreme caution should be
exercised. The menjor experts I interviewed further agreed
that the actual amount of aconite to be added depends on
the strength of the raw material and on the strength of
patient bodies nowadays, resulting in a considerably lower
dose than what is recorded in historical and contemporary
references. The real risk then lies in the uncritical adoption of textual formulas by inexperienced producers, or
not attending to the local ecologies of potency manifested
in the interaction between Tibetan medicinal plants,
skilled producers-with-machines, and the local biologies
of patient bodies. In the clinic, practitioners diagnose the
patient’s constitution and imbalances of the elements and
prescribe medicines as part of a larger treatment regimen
that further considers intricate relationships with food
and environment.
Garuda 5 fulfills its medicinal role within this clinical
encounter as a compound among compounds, which

I described as another level of the balancing act that
maximizes its healing potential. If we approach the activity
of potent substances as a multidimensional spectrum
constituted by its contingent socio-material surroundings,
there is no longer a need for simplistic dose dependencies
or rigid poison/medicine oppositions. This is the case, at
least, for the anthropologist struggling to overcome the
hegemony of structuralist binary opposites. The aim here
is not to falsify or eradicate the conceptual poison/medicine divide, which continues to play a critical role in the
minds of practitioners. I did not focus on how Sowa Rigpa
texts theoretically cross the divide, but instead showed
how this barrier is breached—not without risk—in practice. In this move, I am inspired by Janet Gyatso’s (2015)
historical analysis of scholar-physicians such as Zurkharwa
Lodrö Gyelpo (Zur mkhar ba blo gros rgyal po, 1509–1579),
who forged a more pragmatic and empirical ‘medical
mentality’ in productive tension with classical Buddhist
scholasticism and soteriology.
Understanding categories to be but provisional heuristics that stand for a far more complex
situation on the ground, medical thinkers came to
recognize that opposing taxonomical pairs do not
reference polar opposites in reality. Rather, they
are better understood as markers along axes that
can often be asymmetrical and that in any case
admit a wide array of permutations.
(Gyatso 2015: 400)
Do Tibetan medicines have side effects? From a biomedical
perspective, they might. But this is not the point. Building
on Etkin (1992), ‘side effects’ are an artifact of a reductionist gaze fixated on often only one ‘active substance’
as ‘magic bullet’ targeting a molecular receptor, and the
concomitant assumption that this mechanism automatically leads to a distinguishable ‘primary effect.’ This
view is hardly applicable to Sowa Rigpa, with its flexibly
interpreted multi-compound formulas based on complex
and processed natural ingredients that are indicated for a
spectrum of culturally mediated symptoms and disorders
(see Schwabl and van der Valk 2019). In this sense and
in this sense only, Tibetan medicines indeed do not have
‘side effects.’ This also places general amchi discourse on
drug safety in a different light. I maintain that the material
potency of Tibetan medicines is more coherently explained
by starting with observations of actualized local medical
practice. Promising developments in systems biology
approaches notwithstanding, it is furthermore vital that
Sowa Rigpa’s nuanced conceptualizations of potency,
toxicity, and compounding take center stage in this
endeavor (see Tidwell and Nettles 2019).
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Many Tibetan doctors continue to claim that Sowa Rigpa
formulas are side-effect free as long as they are manufactured authentically and prescribed correctly. Given
the data I have collected, it is impossible to maintain
that Tibetan pills do not have the potential to harm the
patient. It could be argued that it is epistemologically
unfitting to expect the Men-Tsee-Khang to start taking
stock of ‘adverse reactions’ the way science-driven
toxicologists would. This would imply that Sowa Rigpa
needs to be ‘improved’ or ‘modernized’ to be safe, which
simultaneously installs biomedically biased institutions
as the ultimate arbiters of safety, quality, and efficacy. Or
is this perhaps the advent of a uniquely Tibetan alternative modernity that redefinines both ‘tradition’ and
‘modern science’ as mass-produced Tibetan medicines
enter capitalist markets (Kloos 2015)? Such a trajectory
has been followed for more than a decade in the case of
Ayurvedic, Unani, and Siddha drugs. In 2008, a national
pharmacovigilance system was launched under the aegis
of the Department of AYUSH and evaluated in successive
committee meetings, following World Health Organization
guidelines (Chaudhary et al. 2010; Thatte and Bhalerao
2008). The ‘open-minded scientists’ (Ganguly 2012) part of
this program maintain that “[a]lthough a technical term
equivalent to ‘pharmacovigilance’ does not feature in
Ayurvedic texts, the spirit of pharmacovigilance is vibrant
throughout Ayurveda’s classical literature” (Chaudhary et
al. 2010: 252). Notwithstanding possible benefits of such an
approach for practitioners and patients, I argue that the
very opposition between risk and benefit—as found in the
biomedical assessment of risk/benefit ratios of pharmaceuticals32—is misleading when considering the dynamics
of and correlation between toxic and therapeutic effects
in Sowa Rigpa practice. While amchi may think in terms
of duk and men, they also closely attend to and modulate
the local expression of the poison-medicine spectrum in
the pharmacy as well as in the clinic, where they rely on
individual constitutional assessment. Finally, we should take
into account that the very definition of risk and choosing
between risky options is a politically and economically
infused, value-laden selection process that is contingent on
subjective, individual comparisons with daily-life dangers.
Perhaps the risk is higher in some cases, but most likely so
is the benefit. Researchers should not presume the universality of biomedical safety and toxicity notions based on
ethnocentric and paternalistic assumptions. In this light,
the effects of the on-going regulation and standardization of
Sowa Rigpa and other healing traditions on the potency of
their medicines is a topic worthy of further investigation.
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Endnotes
1. The Garuda (Tib. khyung) is a popular mythical creature
in both Hindu and Buddhist traditions which later merged
with the Bonpo ‘sky-soarer’ in Tibet. This king of birds
has the torso of a man and holds a nāga (serpent spirit)
king between his hands and sharp beak. In Tibetan
iconography, the Garuda assumes multiple roles and forms
(Beer 2003: 74-77; see also Karmay 1993). The Garuda 5
origin myth introduced here is also rooted in references
from the Gyüzhi.
2. It appears that Aconitum spp. equally play a role in
the Indian mythical origins of poison. Three alternative
accounts of its origin are depicted and summarized in
Dési Sangyé Gyatso’s monumental seventeenth-century
set of Tibetan medical paintings (see Parfionovitch, Dorje,
and Meyer 1992: 117-118). In the most prominent account
various types of aconite are said to be derived from the
shattered body of Poison Incarnate (Hālahāla), who was
vanquished by the Hindu gods in their quest for the nectar
of immortality.
3. Tibetan medical texts distinguish up to four main color
types of bong nga: white (dkar), red (dmar), yellow (ser),
and black (nag). Only the black type (bong nag) is said to
be “poison as well as medicine” (Dawa 1999: 50, quoting
Rin chen ‘khrungs dpe), and it is subdivided further into
different forms with varying potency (cf. Parfionovitch et
al. 1992: 77, Plate 31). The remaining three types neutralize
different poisons; bong dmar and bong ser in fact alleviate
poisoning by bong nag (Men-Tsee-Khang 2011: 205).

4. Refer to Kloos (2008, 2015, 2017) for the history and the
tightly interlinked cultural aspirations and politics of the
Men-Tsee-Khang in the context of preserving ‘Tibetan
medicine in exile.’ Men-Tsee-Khang positions itself as a
guardian of tradition and is considered by many to be the
prime institution in exile involved in the education and
production of Tibetan medicine.

10. Dr. Tsultim Gyatso, a Men-Tsee-Khang trained monkphysician based in Choglamsar (Ladakh), presented Garuda
5 as an example of a compound exhibiting ‘the potency
of aspirational prayers’ (smon lam gyi nus pa). He related
this to the Garuda legend mentioned in the introduction
(Interview, September 18, 2018). This is, however, just one
small example of a vast and understudied subject.

5. “Alle Dinge sind Gift und nichts ist ohne Gift, allein die
Dosis macht es, dass ein Ding kein Gift ist” (Paracelsus (1538)
1965-1968: 510). The universal validity of this tenet is
also increasingly being challenged by toxicologists,
particularly in light of the chronic toxicity of endocrinedisrupting contaminants, which turns out to be difficult
to predict based on dose-response curves (Myers et al.
2009). More recent biomedical research points out that
timing is equally a crucial factor in the metabolism and
detoxification of drugs (Gachon and Firsov 2011).

11. See Pordié (2014, 2015) for parallel attempts from
the perspective of industrially (re-)engineered Ayurvedic
proprietary medicines.

6. Here, ‘Paracelsian toxicology’ refers to the modern
strand of basic toxicological science built on dosage as the
foundational paradigm. Paracelsus’ own theories of poison
are more complex, varied and idiosyncratic (Hedesan
2018). Grounded in Aristotelian and Christian hierarchical
views of nature as well as Hermetic-alchemical cosmology,
some of his ideas do resonate with Sowa Rigpa. Notable
examples include the reliance on intricate alchemical
procedures to transform poison into medicine, and a
focus on the stomach (the ‘inner alchemist’) and proper
digestion in the elimination of harmful food essences
(conceived as a type of poison).
7. ‘Tibetan medicine’ and its cognates are by far the
most prevalent glosses for Sowa Rigpa (gso ba rig pa, ‘the
science/knowledge of healing’) outside its Himalayan
homelands. I nonetheless prefer the latter, as it is less
ethnocentric and nationalist, and points to the textually
grounded yet heterogeneous nature of this medical
tradition (Adams et al. 2011; Hsu 2013; Craig and Gerke
2016). The spelling ‘Sowa Rigpa’ (not Sowa Rikpa) is
maintained, reflecting common usage.
8. Chan (2009) reports that the estimated lethal dose for
humans is about one gram of fresh plant material or 5 ml
of alcoholic tincture, corresponding to 2 mg of aconitine
and considering that the alkaloid content of the different
plant parts varies significantly (roots and tubers > flowers
> leaves and stems). The most prevalent Chinese medicinal
species are Aconitum carmichaelii Debeaux (fu zi 附子,
lateral roots; chuan wu 川乌, root tuber) and A. kusnezoffii
Rchb. (cao wu 草乌, root tuber).
9. As Craig (2012: 6) notes, the most common Tibetan
translation for efficacy is phan nus. This is a contraction
of the words for benefit (phan thog) and potency (nus pa),
effectively coupling the useful with the powerful.

12. ICTAM stands for International Conference of
Traditional Asian Medicines. It is the main event organised
by IASTAM, the International Association for the Study of
Traditional Asian Medicine.
13. The Central Council for Indian Medicine has recently
officially recognized the medical qualifications of Sowa
Rigpa practitioners who graduated from Men-Tsee-Khang,
as well as three other institutions in India (Indian Medicine
Central Council Act 1970, amended on April 5, 2018). This
implies that registered graduates can legally adopt the title
of ‘Dr.,’ which is also preferred by Men-Tsee-Khang
amchi themselves.
14. In the clinical interactions I observed between amchi
and Tibetan patients at Men-Tsee-Khang’s Gangkyi clinic,
Tibetan medicines were not rarely employed to abate
the side effects perceived by patients undergoing
strong and prolonged biomedical treatments (e.g., for
tuberculosis, hepatitis, and HIV), to support and protect
weakened organs. A similar usage of ma ni ril bu was noted
by Kloos (2010: 114).
15. Several experimental chemical analyses have
confirmed that these traditional processing methods—also
applied in Chinese medicine and Ayurveda—are effective
at the extraction of diester diterpene alkaloids and their
conversion into less toxic monoesters (Jaiswal et al. 2013;
Nyirimigabo et al. 2015; Singhuber et al. 2009).
16. The components (without amounts) and their
correspondence with Garuda body parts, their curative
properties and potential supplementary ingredients
(kha tshar) of Garuda 5 are the first to be listed in the pill
chapter of the Subsequent Tantra (cf. Men-Tsee-Khang
2011b: 90-91). Here, bi kha nag po is the heart of the Garuda.
17. Substitutions across botanical kinds and kingdoms
are not uncommon in Sowa Rigpa (Czaja 2017; Gerke 2016;
Sabernig 2011), and are not easy to explain fully based on
the pharmacological principles of taste and potency.
18. Besides the total percentage of aconite in each
formula, I also calculated the ratio between the weights of
aconite and myrobalan. This second means of comparison
between formulas makes pharmacological sense. A ru ra is
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used in Tibetan medicines as a balancing and detoxifying
agent, it thus neutralises potentially negative effects of the
other ingredients. Phytochemically, chebulic myrobalan
(Terminalia chebula Retz.) is known for its high tannin
content. Tannins bind and precipitate proteinaceous
molecules including alkaloids, which are considered to be
aconite’s major active compounds.
19. This does not reflect all necessary (pre-)processing
and detoxification procedures, neither does it include the
addition of a black ‘iron essence’ (lcags rtsi) pill coating, and
ritually empowered substances. The amounts of several
Men-Tsee-Khang ingredients were left unspecified to
respect their intellectual property rights.
20. Men-Tsee-Khang’s physico-chemical and microbial
quality assessment lab detects the presence/absence of
alkaloids in each batch of raw materials and products
as part of their routine checks, but no standardization
of alkaloid content is carried out as this would require
quantification (and more advanced analytical machinery).
21. ‘Detoxification’ (dug ’don) and ‘taming’ (’dul ba) are
only two amongst several terms and translations used to
denote the processing (Skt. śodhana) of metallic mercury.
Alternatives are ‘cooking,’ ‘purifying,’ and ‘perfecting’
(see Gerke 2013b: 5).
22. Dash (1994, 11-12) warns the reader that tsenduk
(which he considers to be a type of the Ayurvedic
vatsnābha) is exceedingly poisonous and that it should be
detoxified before use, advising prolonged soaking in cow
urine until the purified aconite does not produce tingling
sensations or numbness on the tongue. Khyenrap Norbu
(2007: 151) on the other hand mentions soaking it in eightyear-old child’s urine for three days.
23. Dr. Cairang Nangjia, a Tibetan scholar and practitioner
with an independent clinic (previously affiliated to Qinghai
University’s Tibetan Medical College), informed me that
at Lhasa Mentsikhang bongnak is currently kept for a day
in alcohol to which a bit of musk (gla rtsi) is added before
compounding. At Qinghai’s Provincial Tibetan Hospital
bongnak is boiled in water beforehand, whereas in some
private clinics it is added in unprocessed form. Cairang
Nangjia explained that private doctors who make their
own medicine know the dose and strength of the bongnak
they put. In larger institutions this is not the case, hence
the need to reduce (and standardize) its potency as a safety
precaution (Personal Communication, December 6, 2017).
24. Blaikie (2014: 286) reports that Garuda 5 is also
pervasively prescribed in Ladakh, where the detoxification
of bongnak includes “several hours of constant grinding
by hand while mixing in precise proportions of a ru ra
(Terminalia chebula), which neutralizes its poison.”
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25. In Chinese medicine, boiled aconite roots are also
reported to be tested traditionally through taste: the
absence of tingling and numbing sensations from trying
the decoction implies they are ready for use
(Nyirimigabo et al. 2015: 11).
26. Khyung Nga Nila pills have the same size and color
as the standard Garuda 5 formula, to which some extra
components are added to make it more effective against
sores and skin problems (Dr. Penpa Tsering, Interview, July
18, 2015). Dr. Pasang Yonten Arya learned about this recipe
from the famed Dr. Tenzin Chödrak, and remembered
that detoxified lapis lazuli (mu men, hence ‘nīla’ which
is Sanskrit for ‘blue’) and refined mercury are added
(Personal Communication, August 6, 2016). A third Garuda
formula produced at Men-Tsee-Khang, with a similar
appearance, is Khyung Nga Chuder Chen. Its indications
include bone aches, muscular spasm, and shooting pains
in the limbs.
27. Garuda 5’s beneficial qualities (phan yon) may be
summarized as follows (translated from Penpa Tsering
and Choelothar 2013: 7, which is memorized by fourthyear medical students at Men-Tsee-Khang): “treats
severe stomach pain, inflammation of the head (including
ears, nose, and gums), pain due to intestinal parasites
(srin), tonsillitis, itching and cracking skin, and is
particularly excellent against leprosy and ‘yellow fluid’
(chu ser) disorders. Its potency is neutral, and the mode of
administration mentioned here is four pills taken together
with boiled water.” Interestingly, Garuda 5 is listed as a pill
that cures cold disorders in the Subsequent Tantra (MenTsee-Khang 2011b: 91), whereas pain and inflammation are
usually associated with excess heat.
28. Dr. Penpa Tsering equally felt that Garuda 5 is
prescribed much more by Tibetan doctors nowadays, as
bacterial and viral diseases have become more prevalent
(Interview, July 18, 2015). See Prost (2008: 43-53) for a list
and discussion of diseases and disorders prevalent in the
exile community and their purported causes, and for the
link with social inequalities between different generations
of (migration of) Tibetans (ibid: 54-73).
29. Similarly, Dr. Choelothar mentioned that ga bur is
often taken out of formulations as it is dangerous to
use for patients suffering from ngyan nad; infectious
epidemics such as Hepatitis B and Tuberculosis, which are
locally prevalent in Dharamsala (Barbara Gerke, Personal
Communication, June 2, 2016).
30. A ru ra, chebulic myrobalan, is generally referred to as
the king of medicine (sman gyi rgyal po). The superior type
of a ru, held in the right hand of the Medicine Buddha, is a
panacea for all bodily ailments. Mercury is equally said to
be the king of poison. Camphor is the king of medicines in
the context of hot illness-relieving powders (Chapter 4 of
the Subsequent Tantra).

31. For interpretations beyond the conventional poison/
medicine dichotomy of historical Chinese medical texts,
refer to the foundational work by Paul Unschuld (1975) and
Obringer’s (1997) analysis and comparison with the Greek
term pharmakon.
32. See Keller (1999: 44) and Wiesner (2014) for the
application of the risk/benefit ratio to herbs in the
European context, and van der Valk (2017: 217-228) for
how this plays out for the reformulated Garuda 5 produced
by the Swiss pharmaceutical company PADMA.
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